Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
13.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.05. | TransCode Therapeutics appoints RNA expert to advisory board | 9 | Investing.com | ||
28.05. | TransCode Therapeutics beruft RNA-Experten in den Beirat | 6 | Investing.com Deutsch | ||
08.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 140 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
05.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 250 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
02.05. | TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall | 2 | Seeking Alpha | ||
02.05. | TransCode Therapeutics approves reverse stock split to meet Nasdaq rules | 2 | Investing.com | ||
02.05. | TransCode Therapeutics genehmigt Aktienzusammenlegung zur Einhaltung der NASDAQ-Regeln | 3 | Investing.com Deutsch | ||
02.05. | Transcode Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
02.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 125 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen | |
01.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer | 102 | PR Newswire | A total of 13 patients treated with four escalating doses of TTX-MC138
No significant safety or dose limiting toxicities reported
Two patients have so far maintained... ► Artikel lesen | |
01.05. | EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug | 3 | Benzinga.com | ||
30.04. | Transcode Therapeutics, Inc. - 10-K/A, Annual Report | 4 | SEC Filings | ||
21.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | 13 | SEC Filings | ||
15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | 6 | SEC Filings | ||
31.03. | Transcode Therapeutics, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 5 | SEC Filings | ||
27.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 178 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
25.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | TransCode Therapeutics Announces $10M Stock And Warrant Offering | 1 | RTTNews | ||
24.03. | TransCode Therapeutics stock slides after announces to raise $10M securities offering | 5 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,80 | -0,44 % | Disruption! Ab jetzt wird alles anders: BioNxt Solutions, BioNTech, Bio-Rad Laboratories | Der Ausbruch der Corona-Pandemie hat vieles verändert. Frei nach dem Motto "Einfach mal machen" setzten Unternehmen wie BioNTech auf die mRNA-Technologie. Der Erfolg inklusive Milliardenumsätzen folgte... ► Artikel lesen | |
QIAGEN | 40,690 | -1,43 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
NOVAVAX | 5,680 | +1,39 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
PALATIN TECHNOLOGIES | 0,116 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BRAIN BIOTECH | 1,925 | +0,79 % | BRAIN Biotech: Wann kommt die Trendwende bei den Biokatalysatoren? | Die BRAIN Biotech AG (DE0005203947) kämpft mit einem schwierigen Marktumfeld. Im ersten Halbjahr 2024/25 ging der Umsatz um 7,2 Prozent auf 25,2 Millionen Euro zurück. Das Unternehmen spürt die Auswirkungen... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,770 | +1,72 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
COSCIENS BIOPHARMA | 2,840 | -2,74 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
XOMA ROYALTY | 22,200 | -0,89 % | Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right | EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq-CM:... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,086 | -2,50 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 2,450 | +0,82 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
ORAGENICS | 1,490 | -4,79 % | Oragenics stock tumbles after announcing $20 million preferred stock offering | ||
LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
VIVUS | - | - | Vivus' Qsymia gains market approval in UAE for obesity treatment |